Status:
COMPLETED
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
Acromegaly is a chronic disease, with a high frequency of systemic complications and reduced life span, in cases of persistently active disease. The remission of acromegaly through the surgical remova...
Eligibility Criteria
Inclusion
- patients diagnosed for acromegaly;
- patients underwent first line treatment for acromegaly with pituitary surgery;
- patients with acromegaly diagnosis confirmed through the pathological examination of the resected pituitary tumor;
- patients affected by persistently active acromegaly, after pituitary surgery and consecutively treated with Lanreotide ATG at standard dose;
- patients treated with Lanreotide ATG at standard dose for at least 12 consecutive months and/or patients treated with Lanreotide ATG at standard dose for 6 consecutive months and then at high dose/frequency for at least 12 consecutive month;
- cases with available of all data, required for this study in internal database.
Exclusion
- patients underwent medical therapies or radiotherapy before pituitary surgery;
- patients underwent radiotherapy within 3 years before starting the treatment with Lanreotide ATG;
- patients on treatment with other drugs for acromegaly as dopamine agonist and/or antagonist of GH receptor.
Key Trial Info
Start Date :
January 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06607666
Start Date
January 26 2023
End Date
July 31 2024
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC ENDOCRINOLOGIA
Roma, Italy, 00168